Relapse Risk Assessment for Schizophrenia Patients (RASP): A New Self-Report Screening Tool.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Schizophrenia and Related Psychoses

• Publication date

  2017-11-22

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.3371/CSRP.DVWC.111717PMID 29164930
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Validation of the Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4) Among Patients with Schizophrenia

  2016cited by this paper
• Relapse Risk Assessment in Early Phase Psychosis: The Search for a Reliable and Valid Tool

  2014cited by this paper
• Patient Reported Outcomes Instruments in Schizophrenia: A Review of Psychometric Properties

  2014cited by this paper
• The nature of relapse in schizophrenia

  2013cited by this paper
• Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review

  2013cited by this paper
• Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release

  2013cited by this paper
• Quality of life is predictive of relapse in schizophrenia

  2013cited by this paper
• Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review

  2013cited by this paper
• Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies

  2013cited by this paper
• Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies.

  2012cited by this paper
• Assessing recovery from schizophrenia as an individual process. A review of self-report instruments

  2012cited by this paper
• Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).

  2012cited by this paper
• Testing the Short and Screener versions of the Social Adjustment Scale – Self‐report (SAS‐SR)

  2012cited by this paper
• Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.

  2012cited by this paper
• How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.

  2011cited by this paper
• Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.

  2011cited by this paper
• Quantifying clinical relevance in the treatment of schizophrenia.

  2011cited by this paper
• The cost of relapse and the predictors of relapse in the treatment of schizophrenia

  2010cited by this paper
• Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).

  2010cited by this paper
• The Aggression Questionnaire

  2007cited by this paper
• Stereologic analysis of the lateral geniculate nucleus of the thalamus in normal and schizophrenic subjects.

  2007cited by this paper
• Are self-reports valid for schizophrenia patients with poor insight? Relationship of unawareness of illness to psychological self-report instruments.

  2007cited by this paper
• Social/communication skills, cognition, and vocational functioning in schizophrenia.

  2007cited by this paper
• Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia

  2006cited by this paper
• Health and Quality of Life Outcomes

  2005cited by this paper
• Remission in schizophrenia: proposed criteria and rationale for consensus.

  2005cited by this paper
• The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.

  2004cited by this paper
• A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.

  2002cited by this paper
• The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches.

  2001cited by this paper
• A program for relapse prevention in schizophrenia: a controlled study.

  2000cited by this paper
• Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

  1999cited by this paper
• Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder.

  1998cited by this paper
• On predicting improvement and relapse in generalized anxiety disorder following psychotherapy.

  1997cited by this paper
• The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

  1997cited by this paper
• Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology.

  1997cited by this paper
• Axis V—Global Assessment of Functioning Scale

  1994cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• A rating instrument for anxiety disorders.

  1971cited by this paper
• Patient Related Outcome Measures Dovepress Nonadherence with Antipsychotic Medication in Schizophrenia: Challenges and Management Strategies

  year unknowncited by this paper

• Young Adults' Perspectives on Factors Related to Relapse After First-Episode Psychosis: Qualitative Focus Group Study.

  2022cites this paper
• Analysis Of Factors Affecting Recurrence People With Mental Disorders

  2022cites this paper
• Machine learning for predicting psychotic relapse at 2 years in schizophrenia in the national FACE‐SZ cohort

  2019cites this paper